logo
Plus   Neg
Share
Email

Sorrento : FDA Oks Abivertinib For Phase 2 Study In Patients With Moderate To Severe COVID-19

Sorrento Therapeutics Inc. (SRNE) said that it received clearance from the FDA to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.

In Monday regular trade, SRNE is currently trading at $8.05 up $1.08, or 15.42 percent.

Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).

In May, 2020, Sorrento had entered into a binding term sheet for an exclusive license to ACEA Therapeutics' Abivertinib across all indications for all territories outside of China. The parties have since entered into an exclusive license agreement.

Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer. Most treatment-related adverse events (AEs) were grade 1 or 2, the most common of which were transaminase elevations and diarrhea, which are generally considered common for TKIs.

Other common treatment-related AEs included anemia, neutropenia and thrombocytopenia, each of which are generally considered typical AEs with long-term use of TKIs. No unexpected AEs were reported.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT